Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report

BACKGROUND: Although the BCR-ABL tyrosine kinase inhibitor dasatinib is a potent treatment for chronic myeloid leukaemia, it is associated with the risk of dasatinib-induced pulmonary arterial hypertension (DASA-PAH), for which predisposing factors have yet to be elucidated. However, animal studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Toya, Takumi, Nagatomo, Yuji, Kagami, Kazuki, Adachi, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439368/
https://www.ncbi.nlm.nih.gov/pubmed/31020267
http://dx.doi.org/10.1093/ehjcr/ytz025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439368/
https://www.ncbi.nlm.nih.gov/pubmed/31020267
http://dx.doi.org/10.1093/ehjcr/ytz025

Ejemplares similares